David Goldstein

David M Goldstein, Ph.D. is our Chief Scientific Officer and is a recognized expert in the fields of small molecule drug discovery, kinase inhibitor design and covalent technologies. David has greater than 25 years of industrial experience and has led teams that advanced many small molecule drug candidates into clinical trials in autoimmune diseases and oncology including tolebrutinib, rilzabrutinib and pamapimod. He is a named inventor on more than 40 patents and he has authored more than 40 scientific publications. Most recently, David was the Chief Scientific Officer at Principia Biopharma, a company he helped to launch in 2011 and take public in 2018. Prior to joining Principia, David held positions of increasing responsibility at Roche including Senior Director, Medicinal Chemistry and Head of Inflammation Chemistry. David is currently a Board member of Frontier Medicines in South San Francisco. David received his Ph.D. in Chemistry at the University of Virginia and completed postdoctoral studies in organic chemistry at the University of Pittsburgh.